



POLYPHARMACOLOGY IN DRUG DISCOVERY

Edited by Jens-Uwe Peters

Contents

[*Cover*](#)

[*Title Page*](#)

[*Copyright*](#)

[*Contributors*](#)

[*Preface*](#)

[*Introduction: The Case for Polypharmacology*](#)

[*Part A: Polypharmacology: A Safety Concern in Drug Discovery*](#)

[*Chapter 1: The Relevance of Off-Target Polypharmacology*](#)

[*Chapter 2: Screening for Safety-Relevant Off-Target Activities*](#)

[*2.1 Introduction*](#)

[*2.2 General Aspects*](#)

[*2.3 Selection of Off Targets*](#)

2.4 In Silico Approaches to (Off-Target) Profiling

2.5 Summary and Conclusions

2.6 Acknowledgment

References

Chapter 3: Pharmacological Promiscuity and Molecular Properties

3.1 Introduction: Pharmacological Promiscuity In The History Of Drug Discovery

3.2 Lipophilicity

3.3 Molecular Weight

3.4 Ionization State

3.5 Other Molecular Descriptors and Structural Motifs

3.6 Implications for Drug Discovery
References

Chapter 4: Kinases as Antitargets in Genotoxicity

4.1 Protein Kinases and Inhibitor-Binding Sites

4.2 Cyclin-Dependent Kinases Controlling Unregulated Cell Proliferation

4.3 Mitotic Kinases as Guardians Protecting Cells from Aberrant Chromosome Segregation

4.4 Conclusion

References

Chapter 5: Activity at Cardiovascular Ion Channels: A Key Issue for Drug Discovery

5.1 Introduction

5.2 Screening Methods

5.3 Structural Insights into the Interaction Between Drugs and Cardiovascular Ion Channels

5.4 Medicinal Chemistry Approaches

5.5 Conclusion

References

Chapter 6: Prediction of Side Effects Based on Fingerprint Profiling and Data Mining

6.1 Introduction to BioPrint

6.2 The Pharmacological Fingerprint

6.3 Antidepressant Example

6.4 Profile Similarity at Nontherapeutic Targets

6.5 Interpreting the Polypharmacology Profile

6.6 Methods

6.7 Patterns of Activity

6.8 Integrating Function Profile Data with Traditional Pharmacological Binding Data

6.9 Analysis of the Antifungal Tioconazole

6.10 Conclusions
References

Part B: Polypharmacology: An Opportunity for Drug Discovery.

Chapter 7: Polypharmacological Drugs: “Magic Shotguns” for Psychiatric Diseases

7.1 Introduction

7.2 Definition

7.3 Discovery and Extent of Promiscuity Among Psychiatric Drugs

7.4 Why are so many psychiatric drugs promiscuous?

7.5 Conclusions

References

Chapter 8: Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy

8.1 Targeted Therapies: A New Era in The Treatment of Cancer

8.2 Single-Targeted Therapy

8.3 From Single- to MultiTargeted Drugs in Cancer Therapy

8.4 Polypharmacology Kinase Inhibitors in Clinical Practice and Under Development

References

Chapter 9: Polypharmacology as an Emerging Trend in Antibacterial Discovery

9.1 Introduction

9.2 Classical Antibacterial Polypharmacology

9.3 New Approaches to Multitargeted Single Pharmacophores

9.4 Synthetic Lethals

9.5 Hybrid Molecules

9.6 Conclusions

References

Chapter 10: A “Magic Shotgun” Perspective on Anticonvulsant Mechanisms

10.1 Introduction

10.2 Anticonvulsant Mechanism

10.3 Defining Promiscuity

10.4 Lessons for Promiscuity

10.5 Use of Anticonvulsants in Disorders other than Epilepsy

10.6 Experimental and Theoretical Support for a “Magic Shotgun” Approach

10.7 Current Multitarget Strategies

10.8 Practical Considerations

10.9 Conclusion

Acknowledgments
References

Chapter 11: Selective Optimization of Side Activities (SOSA): A Promising Way for Drug Discovery

11.1 Introduction

11.2 Definition and Principle

11.3 Rationale of SOSA

11.4 Establishing the SOSA Approach

11.5 A Successful Example of the SOSA Approach

11.6 Other Examples of SOSA Switches

11.7 Discussion

11.8 Computer-Assisted Design Using Pharmacophores

11.9 Conclusions

References

Part C: Selected Approaches to Polypharmacological Drug Discovery

Chapter 12: Selective Multitargeted Drugs

12.1 Introduction

12.2 Lead Generation

12.3 Lead Optimization

12.4 Case Studies

12.5 Summary

References

Chapter 13: Computational Multitarget Drug Discovery

13.1 Introduction

**13.2 The Pharmacological Hunt of
Yesteryear**

**13.3 Established Technological
Advancements**

13.4 Computational Drug Discovery

13.5 More Recent Technical Improvements

13.6 Emerging Concepts

13.7 Summary

PostScript

References

Chapter 14: Behavior-Based Screening as an Approach to Polypharmacological Ligands

14.1 The Challenges of CNS Drug Discovery

14.2 In Vivo High-Throughput Screening

14.3 Screening Libraries of Compounds

**14.4 Relationship between Molecular
Properties and In Vivo CNS Activity**

**14.5 Following Screening Hits in Secondary
Assays**

14.6 Potential Therapeutic Value of Dual-Adenosine Compounds

14.7 Summary

References

Chapter 15: Multicomponent Therapeutics

15.1 Introduction

15.2 Why Drug Synergies are Statistically More Context-Dependent

15.3 How a Synergistic Mechanism Can Lead to Therapeutic Selectivity

15.4 Discussion

References

Part D: Case Studies

Chapter 16: Discovery of Sunitinib as a Multitarget Treatment of Cancer

16.1 A Brief Introduction to Tumor Angiogenesis

16.2 Discovery of Sunitinib from Drug Design to First Evidence of Clinical Activity

16.3 Pharmacology of Sunitinib

16.4 Safety of Sunitinib

16.5 Activity of Sunitinib

16.6 Surrogate Imaging Techniques to Capture Vascular Changes

16.7 Surrogate Biomarkers

16.8 Conclusion
References

Chapter 17: Antipsychotics

17.1 Definition and Diagnosis of Schizophrenia

17.2 Etiology and Pathophysiology of Schizophrenia

17.3 Epidemiology

17.4 Medical Practice and Treatment Options

17.5 Case Studies

17.6 CATIE

17.7 Conclusions

References

Chapter 18: Triple-Uptake Inhibitors (Broad-Spectrum Antidepressants)

18.1 Introduction

18.2 The Rationale for Developing Triple-Uptake Inhibitors as Antidepressants

18.3 Preclinical Data

18.4 Clinical Data

18.5 Concluding Remarks

Postscript

References

Chapter 19: Therapeutic Potential of Small Molecules Modulating the

Cyclooxygenase-5-Lipoxygenase Pathway

19.1 Introduction

19.2 Targets of the Eicosanoid Pathway

19.3 Rationale for Development of Dual Inhibitors of the Cyclooxygenase-5-Lipoxygenase Pathway

19.4 Dual Inhibitors of the Cyclooxygenase-5-Lipoxygenase Pathway

19.5 Development of Licofelone

19.6 Conclusions

References

Chapter 20: Drug Research Leading to Imatinib and Beyond to Nilotinib

20.1 Introduction

20.2 Historical Background

20.3 BCR-ABL1 as the Molecular Target for CML Therapy

20.4 Conclusion

References

Chapter 21: Towards Antimalarial Hybrid Drugs

21.1 Introduction

21.2 The History of Malaria Treatment

21.3 Use of Artemisinin and Its Derivatives

21.4 The Search for Hybrid Antimalarials

21.5 Conclusion

Acknowledgments
References

Chapter 22: Multitargeted Drugs for Treatment of Alzheimer's Disease

22.1 Introduction

22.2 Case studies

22.3 Conclusions and Perspectives

References

Chapter 23: Carbonic Anhydrases: Off Targets, Add-on Activities, or Emerging Novel Targets?

23.1 Introduction

23.2 Carbonic Anhydrase Inhibition

23.3 Topiramate and Zonisamide, Antiepileptics with Potent Antiobesity Action

23.4 Sulfonamide Coxibs with Antitumor Activity Due to CA IX/XII Inhibition

23.5 Sulfamates with Steroid Sulfatase and Carbonic Anhydrase Inhibitory Action as Anticancer Agents in Clinical Development

23.6 Lacosamide, an Antiepileptic with a Strange Binding Mode to CA ISOFORMS

23.7 The Protein Tyrosine Kinase Inhibitors Imatinib and Nilotinib as Strong Inhibitors of Several Mammalian CA Isoforms

23.8 Conclusions

Acknowledgments
References

Index

Colour Plates

POLYPHARMACOLOGY IN DRUG DISCOVERY

Edited by

Jens-Uwe Peters

F. Hoffmann-La Roche Ltd. Basel, Switzerland



A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2012 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care

Department within the United States at (800) 762-2974,
outside the United States at (317) 572-3993 or fax (317)
572-4002.

Wiley also publishes its books in a variety of electronic
formats. Some content that appears in print may not be
available in electronic formats. For more information about
Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Polypharmacology in drug discovery / edited by Jens-Uwe
Peters

p. cm.

Includes bibliographical references and index.

ISBN 978-0-470-59090-4 (cloth)

Contributors

Wolfgang Albrecht, c-a-i-r Biosciences GmbH, Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany (w.albrecht@cair-biosciences.de)

Vadim Alexandrov, Psychogenics, Tarrytown, NY 10591

Kamal Azzaoui, Novartis Institutes for BioMedical Research Inc., Fabrikstrasse, Basel, Switzerland (kamal.azzaoui@novartis.com)

Ian M. Bell, Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., PO Box 4, West Point, PA 19486 (ian_bell@merck.com)

Brady Bernard, Institute for Systems Biology, 401 Terry Ave N, Seattle, WA 98109 (bbernard@systemsbiology.org)

Matt Bianchi, Neurology Department, Massachusetts General Hospital, 55 Fruit Street, Wang Ambulatory, Boston, MA 02114 (mtbianchi@partners.org)

Bertrand Billemont, Service Inter-Hospitalier de Cancérologie, Laboratoire de Pharmacobiologie des Anticancéreux (RayLab), U 728 Inserm Université Paris VII, Hôpital Beaujon, 92110 Clichy, France (bertrand.billemont@bjn.aphp.fr)

Mark T. Bilodeau, Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., PO Box 4, West Point, PA 19486 (mtbilodeau@gmail.com)

Maria Laura Bolognesi, Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy (marialaura.bolognesi@unibo.it)

Alexis A. Borisy, Third Rock Ventures, 29 Newbury Street, Boston, MA 02116 (Alexis.Borisy@thirdrockventures.com)

Dani Brunner, Psychogenics, Tarrytown, NY 10591
(Dani.Brunner@psychogenics.com)

Barbara Caldarone, Psychogenics, Tarrytown, NY 10591

Bruce D. Car, Bristol-Myers Squibb Co., Princeton, NJ 08543
(Bruce.Car@bms.com)

Andrea Cavalli, Department of Pharmaceutical Sciences,
University of Bologna, Via Belmeloro 6, I-40126 Bologna,
Italy *and* Department of Drug Discovery and Development,
Italian Institute of Technology, Via Morego 30, I-16163
Genoa, Italy (andrea.cavalli@unibo.it)

Jayaraman Chandrasekhar, Psychogenics, Tarrytown, NY
10591

Kathy Chuang, Neurology Department, Massachusetts
General Hospital, 55 Fruit Street, Wang Ambulatory, Boston,
MA 02114 (kchuang@partners.org)

Camelia Colichi, Service Inter-Hospitalier de Cancérologie,
Laboratoire de Pharmacobiologie des Anticancéreux
(RayLab), U 728 Inserm Université Paris VII, Hôpital Louis
Mourier, 92701 Colombes, France
(camelia.colichi@bjn.aphp.fr)

Catherine Delbaldo, Service Inter-Hospitalier de
Cancérologie, Laboratoire de Pharmacobiologie des
Anticancéreux (RayLab), U 728 Inserm Université Paris VII,
Hôpital Beaujon, 92110 Clichy, France
(catherine.delbaldo@lmr.aphp.fr)

Chantal Dreyer, Service Inter-Hospitalier de Cancérologie,
Laboratoire de Pharmacobiologie des Anticancéreux
(RayLab), U 728 Inserm Université Paris VII, Hôpital Beaujon,
92110 Clichy, France (chantal.dreyer@bjn.aphp.fr)

Sandrine Faivre, Service Inter-Hospitalier de Cancérologie,
Laboratoire de Pharmacobiologie des Anticancéreux

(RayLab), U 728 Inserm Université Paris VII, Hôpital Beaujon, 92110 Clichy, France (sandrine.faivre@bjn.aphp.fr)

Jacques Hamon, Novartis Institutes for BioMedical Research Inc., Fabrikstrasse, Basel, Switzerland (jacques.hamon@novartis.com)

Taleen Hanania, Psychogenics, Tarrytown, NY 10591

Andrew L. Hopkins, Department of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, DD1 5EH, United Kingdom (a.hopkins@dundee.ac.uk)

Jeremy A. Horst, Department of Orofacial Sciences, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94122 (jeremy.horst@ucsf.edu)

Stephan Kirchner, F. Hoffmann-La Roche Ltd., Building 73/207B, CH-4070 Basel, Switzerland (stephan.kirchner@roche.com)

Wesley K. Kroeze, Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27514 (kroeze@email.unc.edu)

Armando A. Lagrutta, Department of Safety Assessment, Merck Research Laboratories, Merck & Co., PO Box 4, West Point, PA 19486 (armando_lagrutta@merck.com)

Thierry Langer, Prestwick Chemical, Boulevard Gonthier d'Andernach, Parc d'Innovation Illkirch-Graffenstaden, 67400 Illkirch, France (thierry.langer@prestwickchemical.fr)

Stefan Laufer, Institute of Pharmacy, University of Tübingen, Tübingen, Germany (stefan.laufer@uni-tuebingen.de)

Adrian Laurenzi, Rosen Building, University of Washington, 960 Republican, Seattle, WA 98109 (alaurenz@uw.edu)

Joseph Lehar, Department of Bioinformatics, Boston University, 44 Cummington Street, Boston, MA 02215 (jlehar@bu.edu)

David Lowe, Psychogenics, Tarrytown, NY 10591

Paul W. Manley, Oncology Department, Novartis Institutes for BioMedical Research, Basel, Switzerland (paul.manley@novartis.com)

Bernard Meunier, Palumed, 3 Rue de l'Industrie, 31320 Castanet-Tolosan, France (b.meunier@palumed.fr)

Jacques Migeon, Cerep Inc., 15318 NE 95th Street, Redmond, WA 98052 (j.migeon@cerep.com)

Dmitri Mikhailov, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139 (dmitri.mikhailov@novartis.com)

Richard Morphy, Medicinal Chemistry Department, MSD Newhouse, Lanarkshire, ML1 5SH, United Kingdom (richard.morphy@spcorp.com)

Jens-Uwe Peters, F. Hoffmann-LaRoche Ltd., Pharmaceuticals Division, Discovery Chemistry, Building/Room 92/3.64C, CH-4070 Basel, Switzerland (jens-uwe.peters@roche.com)

Annalisa Petrelli, Institute for Cancer Research and Treatment, Division of Molecular Oncology, University of Turin Medical School, Strada Provinciale 142, 10060 Candiolo, Italy (annalisa.petrelli@ircc.it)

Eric Raymond, Service Inter-Hospitalier de Cancérologie Beaujon-Bichat, Laboratoire de Pharmacobiologie des Anticancéreux (RayLab), U 728 Inserm Université Paris VII, Hôpital Beaujon, 100 Boulevard du Général Leclerc, 92118 Clichy, France (eric.raymond@bjn.aphp.fr)

Claus Riemer, F. Hoffmann-LaRoche Ltd., Pharmaceuticals Division, Discovery Chemistry, Building/Room 92/3.10C, CH-4070 Basel, Switzerland (claus.riemer@roche.com)

Bryan L. Roth, Department of Pharmacology, University of North Carolina and Department of Psychiatry and Lineberger Cancer Center, School of Medicine, Division of Medicinal Chemistry, School of Pharmacy, *and* National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill, NC 27514 (bryan_roth@med.unc.edu)

Marie-Paule Sablin, Service Inter-Hospitalier de Cancérologie, Laboratoire de Pharmacobiologie des Anticancéreux (RayLab), U 728 Inserm Université Paris VII, Hôpital Beaujon, 92110 Clichy, France (marie-paule.sablin@bjn.aphp.fr)

Ram Samudrala, Rosen Building, University of Washington, 960 Republican, Seattle, WA 98109 (ram@compbio.washington.edu)

Jeff Schneider, Psychogenics, Tarrytown, NY 10591

Lynn L. Silver, LL Silver Consulting, LLC, Springfield, NJ 07081 (silverly@comcast.net)

Phil Skolnick, National Institute on Drug Abuse, National Institutes of Health, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, Bethesda, MD 20892 (phil.skolnick@nih.gov)

Claudio T. Supuran, Dipartimento di Chimica, Laboratorio di Chimica Bioinorganica, University of Florence, Via della Lastruccia, 3, Polo Scientifico, 50019—Sesto Fiorentino (Firenze), Italy (claudio.supuran@unifi.it)

Laszlo Urban, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139 (laszlo.urban@novartis.com)

Camille Georges Wermuth, Prestwick Chemical,
Boulevard Gonthier d'Andernach, Parc d'Innovation Illkirch-
Graffenstaden, 67400 Illkirch, France
(camille.wermuth@prestwickchemical.fr)

Steven Whitebread, Novartis Institutes for BioMedical
Research, 250 Massachusetts Avenue, Cambridge, MA
02139 (steven.whitebread@novartis.com)

Grant R. Zimmermann, Zalicus Incorporated, 245 First
Street, Cambridge, MA 02142 (gzimmermann@zalicus.com)

Jürg Zimmermann, Oncology Department, Novartis
Institutes for BioMedical Research, Basel, Switzerland
(juerg.zimmermann@novartis.com)

Preface

Polypharmacology, the activity of compounds at multiple targets, has been gaining increasing attention since the 1990s, and is currently a hot topic in industrial drug discovery, as well as in academia. The 1990s witnessed the withdrawal of several drugs due to severe adverse effects, which led to permanent injury or deaths, with multi-billion-dollar legal damages. Some of these adverse effects have been linked to unintended interactions with specific off-targets, namely, the serotonin 5HT_{2B} receptor for fenfluramine; the cardiac hERG channel for astemizole, terfenadine, and grepafloxacin; and the M₂ receptor for rapacuronium. During this time, large screening panels were established by drug discovery and contract research organizations, which made it possible to recognize a wide range of off-target activities during the discovery process. As a consequence, more recent research has focused on identifying exquisitely selective drugs, with an expectation to avoid adverse drug reactions (ADRs), to improve compliance, and to gain a competitive advantage over less selective drugs.

On the other hand, the “one drug-one target” paradigm has been increasingly challenged in recent years. Not only has it been associated with a productivity decline throughout the pharmaceutical industry; it has also been increasingly being recognized that the therapy for polygenic diseases benefits more from a polypharmacological approach, which modulates a network of disease-related targets, rather than “switching” a single target on or off. For instance, despite a long quest for selective drugs, all clinically established antipsychotics today are polypharmacological drugs, with the gold standard clozapine having nanomolar activities at more than 25 targets. Polypharmacological therapies are often superior in the prevention of drug resistance, which is a major issue in

the treatment of infections and cancer. In some disease areas, such as inflammatory diseases, the parallel inhibition of redundant disease-relevant pathways may be an attractive strategy for pharmacological intervention. In many instances, the inhibition of several targets may have synergistic therapeutic effects and may thus lead to more efficacious drugs. Additionally, polypharmacological drug discovery provides an opportunity to diversify research, to obtain drug candidates with unique pharmacological profiles, and to avoid a heavy focus on single targets that are often pursued across the whole industry at the same time.

Moreover, the idea that highly selective drugs are inherently safer and better tolerated than multitargeted drugs has been questioned. Rofecoxib may be a point in case; this drug, as well as other “coxibs,” was designed to be more selective, and thus to be safer, than older antiinflammatory drugs such as ibuprofen. Rofecoxib was, however, found to increase the risk for cardiovascular events such as myocardial infarction and stroke. These cardiovascular risks are believed to be the result of rofecoxib's selectivity for one cyclooxygenase isoform, and have led to the withdrawal of this multi-billion-dollar drug in 2004. Another example are the selective serotonin reuptake inhibitors (SSRIs) and serotonin / norepinephrine reuptake inhibitors (SNRIs); although they are considered to be very safe antidepressants, they have a high incidence of unpleasant side effects, which contribute to a high discontinuation rate. These side effects, such as disrupted sleep, sexual dysfunction, and acute nausea and anxiety, are thought to be alleviated by intervention at additional targets. Consequently, several ongoing research programs aim to combine reuptake inhibition with, for example, antagonism at certain serotonin receptors for an improved tolerability. As a more general concept, it has been argued

that polypharmacological drugs can even have a safety advantage, because the modulation of target networks, without permanent, full blockade or activation of a single target, may reduce target-related adverse effects, or may lead to lower efficacious doses.

Thus, there are two sides of the polypharmacology coin: (1) unwanted off-target activities may lead to adverse drug reactions and need to be avoided, while (2) polypharmacological drugs with multiple activities across a disease-relevant target class, such as G-protein-coupled receptors (GPCRs), ion channels, or kinases represent opportunities for improved therapies, as illustrated by the approvals of asenapine (2009), dronedarone (2009), and sunitinib (2006), respectively. Both of these sides will be discussed in this book. For an easy orientation according to the reader's background and interests, the book is divided in four parts:

Part A. Unintended activities at “antitargets” are typically discovered late in the drug discovery process, and have been a reason for late-stage failures, or at least a major hurdle in late lead optimization. The first part of the book discusses concepts and tools that help to recognize, interpret, and address such “antitarget” liabilities early in the drug discovery process, and thus to reduce costly late-stage attrition. Part A opens with an introduction to the relevance of polypharmacology for the safety of drugs, illustrated with salient cases of drugs and drug candidates with off-target-related toxicity. This is followed by an insightful guide to why, when, and how to screen for off-target activities, and how to predict and mitigate potential ADRs. The avoidance of promiscuity-related molecular properties as a strategy to reduce the risk for promiscuity is discussed in the third chapter. Numerous important antitargets will be introduced in these first three chapters, with a focus on GPCR targets. Two other

classes of frequently encountered antitargets, kinases and cardiac ion channels, are discussed next in dedicated chapters. Part A concludes with a chapter on data mining and pharmacological “fingerprint” profiling, which allows for the prediction of otherwise nonobvious ADRs. All this is supported by useful reference information, such as lists of off-targets associated with potential ADRs, frequently hit off-targets, and practical examples of lead optimization.

Part B. The productivity of the drug discovery industry as a whole has declined since the 1990s, with only ~20 new chemical entities per year reaching the market, despite ever-increasing research budgets. New discovery paradigms are therefore necessary to deviate from established research strategies, and to address those unmet medical needs that do not succumb to the ubiquitous “small molecule-single target protein” approach. Multitargeted, or polypharmacological, drug discovery may present opportunities where conventional approaches have been failing, especially for the treatment of diseases with multiple pathogenic factors, and diseases where resistance poses an important problem. Part B highlights four such disease areas: psychiatric diseases, cancer, bacterial infections, and epilepsy. Although the introductory chapter is dedicated to psychiatric drugs, the concepts discussed are instructive and generally applicable. In contrast to the antischizophrenia drugs, which were originally discovered serendipitously without knowledge of their polypharmacological nature, more recently approved kinase inhibitors for the treatment of cancer were developed with the knowledge of their polypharmacology, or were even deliberately designed to be polypharmacological, as outlined in the second chapter. The third chapter shows that most clinically established

antibiotics rely on the inhibition of several targets, or targets encoded by multiple genes. In contrast, targets encoded by single genes, such as those obtained from bacterial genomes, have not led to novel antibacterials, or are associated with rapid resistance mutations. The fourth chapter shows how antiepilepsy drugs often enhance or inhibit multiple ligand- or voltage-gated ion channels, and proposes a strategy for the discovery of novel, multitargeted antiepilepsy therapies. The final chapter of the “opportunity” part of the book is not related to a disease area, but rather highlights an approach to lead finding that exploits the polypharmacology of existing drugs: the selective optimization of side activities (SOSA). This approach has been historically very successful, but has been neglected in more recent years in favor of high-throughput screening. The chapter shows how this concept can be revived and complemented with modern *in silico* methods. As Sir James Black states: “The most fruitful basis for the discovery of a new drug is to start with an old drug.”

Part C. Most of today's “multitargeted” drug discovery programs seem to have originated from the serendipitous discovery of dual, and sometimes multiple, ligands of often related disease-relevant targets. Apart from such obvious opportunities, multitargeted drug discovery is often perceived as not very feasible by industrial researchers, because of the more difficult lead finding, and the increased complexity of lead optimization. To illustrate how multitargeted drug discovery can be put into practice, a number of selected approaches are presented in Part C. The first chapter discusses how starting points for multitargeted drug discovery programs may be obtained either by screening or rational framework combination, and how such compounds can be

optimized. This is illustrated with many examples. The *in silico* approaches for multitarget screening can be employed to find multitargeted drugs or repurposing opportunities for existing drugs. This is discussed in the second chapter, with a focus on the 2010 NIH Director's Pioneer Award-winning CANDO method. This chapter provides also a detailed introduction to *in silico* screening in general, and will certainly attract the interest of *in silico* experts and nonspecialists alike. The third chapter introduces an intriguing method of high-throughput *in vivo* screening, in which a large number of behavioral readouts are automatically recognized, processed, and compared with a database of behavioral signatures of central nervous system (CNS)-active drugs. Such methods may constitute a modern version of the physiologically based screening paradigm that was the mainstay of the golden era of drug discovery. Many other possibilities are perhaps more obvious and do not warrant a detailed discussion. For instance, the mining of proprietary high-throughput screening (HTS) or safety panel data, or commercial or public pharmacological databases may be a rich source of multitargeted leads as starting points for discovery projects. Also, the “anticonvulsants” chapter of Part B proposes a generally applicable screening strategy, where novel multitargeted leads are sought to mimic the profile of successful drugs. Finally, Part C is rounded off with an introduction to multicomponent therapeutics, and shows how combinations of drugs can be selectively synergistic for therapeutic versus adverse effects, because the drug targets of the components are expressed together only in the tissue that is responsible for the therapeutic effect.

Part D. The last part is a collection of various instructive case studies. Most of the chapters in this part are dedicated to the discovery of polypharmacological or

specifically multitargeted drugs, ranging from the highly promiscuous anticancer drug sunitinib and antipsychotics over broad-spectrum antidepressants to the dual-acting drug candidate licofelone for inflammatory diseases. The achievement of (reasonable) selectivity in the kinase field, and activity across mutant targets, is discussed in the imatinib case study. An untypical type of dual activity is displayed by the experimental drug PA1103, which is able to inhibit the polymerization of heme, as well as to alkylate heme, both validated concepts for the treatment of malaria. The penultimate chapter discusses multitargeted approaches to the treatment of Alzheimer's disease, and specific clinical and preclinical compounds. A final chapter is dedicated to the (off-target) activities of established drugs at carbonic anhydrases; this chapter illustrates the potential of target discovery, drug repurposing and the discovery of new drugs based on the polypharmacology of existing pharmaceuticals. Throughout Part D, many authors express their personal views on the future of polypharmacological drug discovery. These views, ranging from slight skepticism to enthusiasm, may provide the reader with a balanced and realistic impression of the promises and challenges of polypharmacological drug discovery.

This book is intended as a practical guide for drug hunters to successfully navigate around the dangers of promiscuous ligands and targets, as well as a source of inspiration for new polypharmacological drug discovery projects. However, this collection of reviews, opinions, and case studies is by no means an exhaustive treatment of all possible facets of polypharmacology. For instance, drug-drug interactions are not treated; although formally a polypharmacology issue, this is usually regarded as DMPK-related, and several excellent books cover this important topic. Similarly, pleiotropic effects through interaction with single targets,

the achievement of selectivity across related targets or within target classes, or the contribution of active metabolites to the pharmacological spectra of drugs may be regarded as “polypharmacology topics,” but were considered to be beyond scope of this text.

I am very grateful to the contributing authors, who invested their time and expertise in this book. Also, I would like to thank Jonathan Rose at Wiley for proposing this book, and for his continuous advice and support throughout this project.

Note: Color versions of select figures are available at ftp://ftp.wiley.com/public/sci_tech_med/polypharmacology.

Jens-Uwe Peters

Basel, Switzerland

November 2011